Monte Rosa Therapeutics (GLUE)
US Market

Monte Rosa Therapeutics (GLUE) Cash flow


Monte Rosa Therapeutics Cash Flow

GLUE's free cash flow for Q3 2023 was $―. For the 2023 fiscal year, GLUE's free cash flow was decreased by $74.39M and operating cash flow was $-24.71M. See a summary of the company’s cash flow.
Cash Flow
Dec 22Dec 21Dec 20Dec 19
Operating Cash Flow
$ -72.02M$ 5.34M$ -59.40M$ -23.05M$ -6.17M
Investing Cash Flow
$ 2.02M$ -219.22M$ -9.65M$ -3.39M$ -1.39M
Financing Cash Flow
$ 21.55M$ 20.47M$ 377.56M$ 60.06M$ 15.00M
Cash Flow From Discontinued Operation
Other Cash Adjustment Inside Changein Cash
End Cash Position
$ 180.99M$ 5.34M$ 351.38M$ 42.86M$ 9.24M
Income Tax Paid Supplemental Data
Interest Paid Supplemental Data
Issuance Of Capital Stock
$ 20.32M$ 20.03M$ 237.75M$ 60.50M$ 14.25M
Issuance Of Debt
---$ 0.00$ 750.00K
Repayment Of Debt
Free Cash Flow
$ -63.77M$ 5.34M$ -69.05M$ -26.44M$ -7.56M
Domestic Sales
Foreign Sales
Currency in USD

Monte Rosa Therapeutics Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis